Weight reduction and long-term maintenance after 18 months treatment with orlistat for obesity

Krempf, Michel; Jp, Louvet; Allanic, H; Miloradovich, T; Jm, Joubert; Attali, J. R.

doi:10.1038/sj.ijo.0802281

Cited by 77 publications

(72 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…19,20,36,[58][59][60]62,[64][65][66][67][68][69][70]72,74 Intervention participants were more likely to lose ≥ 10% of their baseline body weight compared with controls. There was no evidence that the effect of treatment differed based on focus of intervention (Table 3).…”

Section: Weight Outcomesmentioning

confidence: 99%

See 1 more Smart Citation

Treatment for overweight and obesity in adult populations: a systematic review and meta-analysis

et al. 2014

View full text Add to dashboard Cite

Section: Weight Outcomesmentioning

confidence: 99%

“…[58][59][60][61]64,66,67,[69][70][71][72][73][74]82,84 However, as indicated by the test for subgroup differences, participants in the 15 pharmacologic interventions were significantly more likely to have an adverse event (Table 5).…”

Section: Adverse Effectsmentioning

confidence: 99%

Treatment for overweight and obesity in adult populations: a systematic review and meta-analysis

et al. 2014

View full text Add to dashboard Cite

“…Experts recommend regular longitudinal monitoring and careful documentation of BMI among children and adolescents. 125 Such monitoring will likely prove even more valuable as our understanding grows about the predictive value of levels and patterns of growth and overweight status changes over time and about effective ways to address patterns that indicate overweight that affects current health or a high future risk of adult overweight.…”

Section: E138mentioning

confidence: 99%

Screening and Interventions for Childhood Overweight: A Summary of Evidence for the US Preventive Services Task Force

et al. 2005

View full text Add to dashboard Cite

ABSTRACT. Background. Childhood and adolescent overweight and obesity are related to health risks, medical conditions, and increased risk of adult obesity, with its attendant effects on morbidity and mortality rates. The prevalence of childhood overweight and obesity has more than doubled in the past 25 years.Purpose. This evidence synthesis examines the evidence for the benefits and harms of screening and early treatment of overweight among children and adolescents in clinical settings.Methods. We developed an analytic framework and 7 key questions representing the logical evidence connecting screening and weight control interventions with changes in overweight and behavioral, physiologic, and health outcomes in childhood or adulthood. We searched Results. Although BMI is a measure of relative weight rather than adiposity, it is recommended widely for use among children and adolescents to determine overweight and is the currently preferred measure. The risk of adult overweight from childhood overweight provides the best available evidence to judge the clinical validity of BMI as an overweight criterion for children and adolescents. BMI measures in childhood track to adulthood moderately or very well, with stronger tracking seen for children with >1 obese parent and children who are more overweight or older. The probability of adult obesity (BMI of >30 kg/m 2 ) is >50% among children >13 years of age whose BMI percentiles meet or exceed the 95th percentile for age and gender. BMI-based overweight categorization for individuals, particularly for racial/ethnic minorities with differences in body composition, may have limited validity because BMI measures cannot differentiate between increased weight for height attributable to relatively greater fat-free mass (muscle, bone, and fluids) and that attributable to greater fat. No trials of screening programs to identify and to treat childhood overweight have been reported. Limited research is available on effective, generalizable interventions for overweight children and adolescents that can be conducted in primary care settings or through primary care referrals.Conclusions.

show abstract

“…Orlistat, a widely used drug, reduces the absorption of dietary fat in the intestine by inhibiting lipase enzyme activity, and may lower serum cholesterol and triglyceride levels. 16,21 Therefore, orlistat may be expected to affect serum leptin levels.…”

Section: Discussionmentioning

confidence: 99%

“…Orlistat (tetrahydrolipstatin), a widely used antiobesity drug, could reduce the absorption of dietary fat from the intestinal lumen by inhibiting pancreatic lipase enzyme activity, and may lower serum cholesterol and triglyceride levels. 16 It is logical to expect that orlistat also may have an effect on serum leptin levels. The impact of body weight loss induced by orlistat on serum leptin levels in obese patients has not been extensively studied, according to a MEDLINE search (key terms, orlistat, leptin, and weight loss; years, 1974-2004).…”

Section: Introductionmentioning

confidence: 99%

Effects of a weight-reduction program with orlistat on serum leptin levels in obese women: A 12-week, randomized, placebo-controlled study

Özçelik

Doğan

Keleştimur

2004

Current Therapeutic Research

View full text Add to dashboard Cite

Background: Leptin, which has been identified as an antiobesity hormone, regulates body weight by controlling food intake and energy expenditure via the hypothalamic-pituitary-gonadal axis. It appears that leptin may be an important factor in obesity management. Orlistat, a pancreatic lipase inhibitor, could reduce fat absorption and promote weight loss due to leptin metabolism.Objective: The purpose of this study was to investigate the effects of orlistat therapy on serum leptin levels.Methods: Obese women (body mass index [BMI], 30 kg/m 2 ) aged 18 to 50 years were randomly assigned to receive 12 weeks of oral treatment with diet-orlistat (120 mg TID) (DO group) or diet-placebo (DP group). During the treatment period, patients were asked to eat a balanced diet of ∼1200 to 1600 kcal/d. Body composition was determined by bioelectrical impedance. Serum leptin levels were measured using radioimmunoassay at baseline and at study end.Results ) received placebo. Compared with baseline, mean percentages of loss of body weight and fat mass after 12 weeks of treatment were significant in the DO group (9.1% and 14.8%, respectively; both P = 0.001) and in the DP group (9.5% and 17.6%; both P = 0.005). The between-group differences were not statistically significant. Mean (SE) serum leptin levels also decreased significantly after treatment in the DO group (16.2 [1.2] vs 9.0 [1.0] ng/mL; P = 0.001) and in the DP group (19.3 [2.1] vs 9.7 [1.4] ng/mL; P = 0.005). The between-group difference was not statistically significant.Conclusions: In this study of obese women, orlistat treatment was associated with a similar decrease in body weight, fat mass, and serum leptin levels Accepted for publication January 20, 2004. Reproduction in whole or part is not permitted.0011-393X/04/$19.00 as placebo over a 12-week period. In this regard, short-term orlistat therapy may not provide an additional effect on serum leptin levels, and reduction in leptin levels were closely related to the decrease in fat mass. (Curr Ther Res Clin Exp. C U R R E N T T H E R A P E U T I C R E S E A R C H ாV

show abstract

Weight reduction and long-term maintenance after 18 months treatment with orlistat for obesity

Cited by 77 publications

References 14 publications

Treatment for overweight and obesity in adult populations: a systematic review and meta-analysis

Treatment for overweight and obesity in adult populations: a systematic review and meta-analysis

Screening and Interventions for Childhood Overweight: A Summary of Evidence for the US Preventive Services Task Force

Effects of a weight-reduction program with orlistat on serum leptin levels in obese women: A 12-week, randomized, placebo-controlled study

Contact Info

Product

Resources

About